Related Experiment Videos
[Clinical evaluation of clarithromycin, a new macrolide antibiotic in children]
Insights
A new macrolide antibiotic, clarithromycin (TE-031), demonstrated effectiveness and good safety in treating various pediatric infections. Its pharmacokinetic profile in children suggests improved absorption compared to older macrolides.
Area of Science:
- Infectious Diseases
- Pediatric Medicine
- Pharmacology
Context:
- Antibiotic resistance necessitates novel therapeutic agents.
- Macrolides are a crucial class of antibiotics for bacterial infections.
- Pediatric populations often have unique pharmacokinetic and safety considerations.
Purpose:
- To evaluate the safety, efficacy, and pharmacokinetics of a new oral macrolide, clarithromycin (TE-031), in pediatric patients.
- To compare the pharmacokinetic availability of TE-031 with older macrolide antibiotics.
- To assess the clinical utility of TE-031 in treating common pediatric infectious diseases.
Summary:
- Clarithromycin (TE-031) was administered to 33 children with various infections, including mycoplasmal pneumonia, pneumococcal pneumonia, streptococcal pharyngitis, pertussis, and Campylobacter gastroenteritis.
- The drug proved effective in all treated cases.
- Pharmacokinetic studies indicated significantly better availability for TE-031 (granules and tablets) compared to older macrolides, with an average serum half-life of 3.2 +/- 0.25 hours for the granule preparation.
- No significant adverse reactions were observed, though two cases each of transient mild elevation in serum GPT and eosinophilia were noted.
Impact:
- TE-031 shows promise as a safe and effective treatment option for a range of infectious diseases in children.
- Improved pharmacokinetic properties may lead to more convenient dosing regimens.
- These preliminary findings support the potential integration of TE-031 into pediatric infectious disease treatment protocols.
Abstract:
A new oral macrolide, clarithromycin (TE-031, A-56268), was evaluated for its safety, efficacy and pharmacokinetics in 33 children. TE-031 was effective in all cases of mycoplasmal pneumonia, pneumococcal pneumonia, streptococcal pharyngitis, pertussis and Campylobacter gastroenteritis. The pharmacokinetic availability of TE-031 granule and tablets was much better than the older macrolides; serum half-lives of TE-031 averaged 3.2 +/- 0.25 hours (for the granule preparation). No clinical adverse reaction was encountered, but cases of transient mild elevation of the serum GPT (2 cases) and eosinophilia (2 cases) were encountered. From these preliminary data, TE-031 seems to have a place in the treatment of pediatric infectious diseases.